<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">

  <!-- PACE Progress Bar START -->
  
    
<script src="https://raw.githubusercontent.com/HubSpot/pace/v1.0.2/pace.min.js"></script>

    
<link rel="stylesheet" href="https://github.com/HubSpot/pace/raw/master/themes/orange/pace-theme-flash.css">

  
  

  <!-- PACE Progress Bar START -->

  
  <title>Hexo</title>
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
  
  
  
  
  <meta name="description" content="文章来源： 《经济学人》Jun 12th 2021 期Science &amp; technology 栏目 America’s wary approval of an Alzheimer’s drug offers hope to millions美国对一种治疗老年痴呆症的药物的谨慎批准给数百万人带来了希望 A flicker of light闪现的光 ![image-2021061411583">
<meta property="og:type" content="article">
<meta property="og:title" content="Hexo">
<meta property="og:url" content="http://example.com/2021/06/14/Day419-The%20Economist/index.html">
<meta property="og:site_name" content="Hexo">
<meta property="og:description" content="文章来源： 《经济学人》Jun 12th 2021 期Science &amp; technology 栏目 America’s wary approval of an Alzheimer’s drug offers hope to millions美国对一种治疗老年痴呆症的药物的谨慎批准给数百万人带来了希望 A flicker of light闪现的光 ![image-2021061411583">
<meta property="og:locale" content="en_US">
<meta property="article:published_time" content="2021-06-14T03:57:17.124Z">
<meta property="article:modified_time" content="2021-06-14T03:58:39.897Z">
<meta property="article:author" content="John Doe">
<meta name="twitter:card" content="summary">
  
    <link rel="alternate" href="/atom.xml" title="Hexo" type="application/atom+xml">
  
  <link rel="icon" href="/css/images/favicon.ico">
  
    <link href="//fonts.googleapis.com/css?family=Source+Code+Pro" rel="stylesheet" type="text/css">
  
  <link href="https://fonts.googleapis.com/css?family=Open+Sans|Montserrat:700" rel="stylesheet" type="text/css">
  <link href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic" rel="stylesheet" type="text/css">
  <link href="https://cdn.bootcss.com/font-awesome/4.6.3/css/font-awesome.min.css" rel="stylesheet">
  <style type="text/css">
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/9749f0/00000000000000000001008f/27/l?subset_id=2&fvd=n5) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/90cf9f/000000000000000000010091/27/l?subset_id=2&fvd=n7) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/8a5494/000000000000000000013365/27/l?subset_id=2&fvd=n4) format("woff2");font-weight:lighter;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/d337d8/000000000000000000010095/27/l?subset_id=2&fvd=i4) format("woff2");font-weight:400;font-style:italic;}</style>
    
  <link rel="stylesheet" id="athemes-headings-fonts-css" href="//fonts.googleapis.com/css?family=Yanone+Kaffeesatz%3A200%2C300%2C400%2C700&amp;ver=4.6.1" type="text/css" media="all">
  
<link rel="stylesheet" href="/css/style.css">


  
<script src="https://code.jquery.com/jquery-3.1.1.min.js"></script>


  <!-- Bootstrap core CSS -->
  <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/bootstrap/3.0.2/css/bootstrap.min.css" >
  <link rel="stylesheet" href="/css/hiero.css" >
  <link rel="stylesheet" href="/css/glyphs.css" >
  
    <link rel="stylesheet" href="/css/vdonate.css" >
  

  <!-- Custom CSS -->
  
<link rel="stylesheet" href="/css/my.css">

  <!-- Google Adsense -->
  
  <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
  <script>
      (adsbygoogle = window.adsbygoogle || []).push({
          google_ad_client: "ca-pub-0123456789ABCDEF",
          enable_page_level_ads: true
      });
  </script>
  
<meta name="generator" content="Hexo 6.3.0"></head>

<script>
var themeMenus = {};

  themeMenus["/"] = "Home"; 

  themeMenus["/archives"] = "Archives"; 

  themeMenus["/categories"] = "Categories"; 

  themeMenus["/tags"] = "Tags"; 

  themeMenus["/about"] = "About"; 

</script>


  <body data-spy="scroll" data-target="#toc" data-offset="50">


  <header id="allheader" class="site-header" role="banner">
  <div class="clearfix container">
      <div class="site-branding">

          <h1 class="site-title">
            
              <a href="/" title="Hexo" rel="home"> Hexo </a>
            
          </h1>

          
            
          <nav id="main-navigation" class="main-navigation" role="navigation">
            <a class="nav-open">Menu</a>
            <a class="nav-close">Close</a>
            <div class="clearfix sf-menu">

              <ul id="main-nav" class="nmenu sf-js-enabled">
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/">Home</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/archives">Archives</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/categories">Categories</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/tags">Tags</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/about">About</a> </li>
                    
              </ul>
            </div>
          </nav>


      </div>
  </div>
</header>


  <div id="originBgDiv" style="background: #fff; width: 100%;">

      <div style="max-height:600px; overflow: hidden;  display: flex; display: -webkit-flex; align-items: center;">
        <img id="originBg" width="100%" alt="" src="">
      </div>

  </div>

  <script>
  function setAboutIMG(){
      var imgUrls = "css/images/pose.jpg,https://source.unsplash.com/collection/954550/1920x1080".split(",");
      var random = Math.floor((Math.random() * imgUrls.length ));
      if (imgUrls[random].startsWith('http') || imgUrls[random].indexOf('://') >= 0) {
        document.getElementById("originBg").src=imgUrls[random];
      } else {
        document.getElementById("originBg").src='/' + imgUrls[random];
      }
  }
  bgDiv=document.getElementById("originBgDiv");
  if(location.pathname.match('about')){
    setAboutIMG();
    bgDiv.style.display='block';
  }else{
    bgDiv.style.display='none';
  }
  </script>



  <div id="container">
    <div id="wrap">
            
      <div id="content" class="outer">
        
          <section id="main" style="float:none;"><article id="post-Day419-The Economist" style="width: 66%; float:left;" class="article article-type-post" itemscope itemprop="blogPost" >
  <div id="articleInner" class="clearfix post-1016 post type-post status-publish format-standard has-post-thumbnail hentry category-template-2 category-uncategorized tag-codex tag-edge-case tag-featured-image tag-image tag-template">
    
    
    <div class="article-meta">
      
	Posted on <a href="/2021/06/14/Day419-The%20Economist/" class="article-date">
	  <time datetime="2021-06-14T03:57:17.124Z" itemprop="datePublished">June 14, 2021</time>
	</a>

      
	<span id="busuanzi_container_page_pv">
	  本文总阅读量<span id="busuanzi_value_page_pv"></span>次
	</span>

    </div>
    <div class="article-entry" itemprop="articleBody">
      
        <p><strong>文章来源： 《经济学人》Jun 12th 2021 期Science &amp; technology 栏目</strong></p>
<h1 id="America’s-wary-approval-of-an-Alzheimer’s-drug-offers-hope-to-millions"><a href="#America’s-wary-approval-of-an-Alzheimer’s-drug-offers-hope-to-millions" class="headerlink" title="America’s wary approval of an Alzheimer’s drug offers hope to millions"></a>America’s wary approval of an Alzheimer’s drug offers hope to millions</h1><p>美国对一种治疗老年痴呆症的药物的谨慎批准给数百万人带来了希望</p>
<h6 id="A-flicker-of-light"><a href="#A-flicker-of-light" class="headerlink" title="A flicker of light"></a>A flicker of light</h6><p>闪现的光</p>
<p>![image-20210614115837856](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&#x2F;image-20210614115837856.png)</p>
<h5 id="But-its-makers-still-have-work-to-do-to-prove-it-can-slow-the-advance-of-dementia"><a href="#But-its-makers-still-have-work-to-do-to-prove-it-can-slow-the-advance-of-dementia" class="headerlink" title="But its makers still have work to do to prove it can slow the advance of dementia"></a>But its makers still have work to do to prove it can slow the advance of dementia</h5><p>dementia 痴呆</p>
<p>但是它的制造者仍然要做很多工作来证明它可以减缓痴呆症的发展</p>
<blockquote>
<p>Jun 10th 2021 </p>
</blockquote>
<p><strong>NEWS</strong> THAT America’s Food and Drug Administration (FDA) has granted conditional approval to a new drug, aducanumab, to be marketed as Aduhelm, for the treatment of Alzheimer’s disease, <strong>has understandably been greeted as a huge breakthrough.</strong> For millions of people with Alzheimer’s, a remorselessly degenerative illness leading eventually to utter helplessness—and for those caring for them—<strong>it is a ray of hope</strong>. But the benefits it will offer remain uncertain, and the FDA’s decision is controversial.</p>
<blockquote>
<p>remorselessly 无情地; 无休止地</p>
<p>degenerative 变性的</p>
</blockquote>
<p>美国食品和药物管理局(FDA)有条件批准了一种新药aducanumab，该药将作为Aduhelm上市，用于治疗阿尔茨海默氏症。这一消息被认为是一个巨大的突破，这是可以理解的。对于数以百万计的阿尔茨海默氏症患者来说，这是一种无情的退化性疾病，最终会导致彻底的无助，而对于那些照顾他们的人来说，这是一线希望。但是它所能带来的好处仍然不确定，FDA的决定也存在争议。</p>
<p>It was 115 years ago that Alois Alzheimer, a German psychiatrist, conducted the autopsy that helped him identify the disease now known as Alzheimer’s. <strong>It is much the most common of the dozens of causes of dementia.</strong> It accounts for 60-80% of cases of a debilitating condition that affects an estimated 50m people around the world, and—as the risk of dementia increases with age, and the world is getting older—is spreading fast. The costs in human misery are incalculable. In terms of expenditure in caring for people with the condition, they are estimated at over $1trn now, and forecast to reach $2trn by 2030. </p>
<blockquote>
<p>psychiatrist 精神病专家</p>
<p>autopsy 验尸</p>
<p>debilitate 使虚弱; 削弱…的力量</p>
</blockquote>
<p>115年前，德国精神病学家Alois Alzheimer进行了尸检，帮助他确定了现在被称为阿尔茨海默氏症这一疾病。它是痴呆的几十种原因中最常见的。据估计世界上大约有5000万人患有衰弱性疾病，而痴呆症占了这种衰弱性疾病的60% -80%。随着年龄的增长，患痴呆症的风险也在增加，世界老龄化的趋势也在加重，而且痴呆症这一情况正在迅速蔓延。人类苦难的代价是无法估量的。在照顾这类患者方面，目前估计支出超过1万亿美元，预计到2030年将达到2万亿美元。</p>
<p>So even if few have hoped for an imminent cure there is huge pent-up demand for a treatment that at least slows the advance of Alzheimer’s. The FDA claims in its press release on the approval sought by Biogen, a biotechnology firm based in Cambridge, Massachusetts: “Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease.” In November 2019 China granted conditional approval to Oligomannate (gv-971), a drug produced by Green Valley, a company from Shanghai. But Western scientists grumbled the data from the Chinese study were scanty and its conclusions <strong>hard to credit</strong>. </p>
<blockquote>
<p>pent-up 压抑的; 积压的</p>
<p>scanty 量少的；不足的</p>
</blockquote>
<p>因此，即使人们并没有希望能很快治愈老年痴呆症，但对一种至少能减缓老年痴呆症发展的治疗方法，仍有巨大的被压抑的需求。美国食品药品监督管理局(FDA)在Biogen（总部位于马萨诸塞州剑桥市的生物技术公司）正在寻求批准的新闻稿中声称：“Aduhelm是第一个针对阿尔茨海默病潜在病理生理学的治疗方法。”2019年11月，中国有条件批准了上海Green Valley公司生产的药物Oligomannate (gv-971)。但西方科学家抱怨中国的研究数据不足，其结论难以可信。</p>
<p><strong>So the jubilation in some quarters at Biogen’s coup is understandable.</strong> But it is not universal, <strong>in part because of</strong> the tortuous history of the drug’s progress to approval. It is of a type known as a monoclonal antibody—a specialised protein molecule forming part of the immune system—tailored to bind to a protein called beta-amyloid, which forms plaques in the brains of people with Alzheimer’s disease, and which many researchers have long believed is not just a symptom of Alzheimer’s but at least part of the cause (an idea known as “the amyloid hypothesis”). Aducanumab does, indeed, seem to reduce the amount of beta-amyloid in the brain. That is why the FDA has approved it. The theory is that this should, in turn, slow the progress of cognitive degeneration. On that point, the evidence is less clear-cut. The FDA approval allows the drug to be used but requires Biogen to carry out a large-scale clinical trial to prove that it does indeed work, and warns that if not, it could be “pulled from the market”.</p>
<blockquote>
<p>jubilation 欢腾；欢庆</p>
<p>quarters 群体</p>
<p>coup 突然的成功之举</p>
<p>tortuous 曲折的</p>
</blockquote>
<p>因此，一些人对Biogen的突然成功欢呼雀跃是可以理解的。但它并不是普遍适用的，部分原因是该药物在获得批准的过程中经历了曲折的历史。它属于单克隆抗体（一种形成部分免疫系统的特异性蛋白质分子），专门与一种叫做β -淀粉样蛋白的蛋白质结合，β -淀粉样蛋白会在老年痴呆症患者的大脑中形成斑块，许多研究人员长期以来一直认为这不仅仅是阿尔茨海默氏症的症状，而且至少是其部分原因(这个想法被称为“淀粉样蛋白假说”)。Aducanumab似乎确实减少了大脑中的β -淀粉样蛋白的数量。这就是FDA批准它的原因。该理论认为，这反过来应该会减缓认知退化的进程。在这一点上，证据就并不那么明确。FDA的批准允许使用这种药物，但要求Biogen进行大规模临床试验，以证明它确实有效，并警告说，如果不这样做，该药可能被“撤市”。</p>
<p>Previous efforts to demonstrate its efficacy appeared to have foundered in March 2019, when Biogen and Eisai of Japan announced that they were ending two clinical trials among people with signs of mild cognitive impairment or early-onset Alzheimer’s. Aducanumab had failed a “futility test”—ie, the evidence suggested it had no effect. But then, in October that year, Biogen said <strong>a fresh look at the data</strong> showed that “patients…<strong>experienced significant benefits</strong> on measures of cognition and function such as memory, orientation and language.” One of the two trials, it said, showed that higher doses of the drug did <strong>have a small but noticeable effect</strong> in slowing cognitive decline in people with Alzheimer’s. Biogen said it would seek FDA approval after all. </p>
<blockquote>
<p>founder 失败</p>
</blockquote>
<p>此前证明其疗效的努力似乎在2019年3月宣告失败，当时Biogen和日本的Eisai宣布，他们将结束对有轻度认知障碍或早发性阿尔茨海默症症状的人进行的两项临床试验。Aducanumab没有通过“无效测试”——也就是说，证据表明它没有效果。但同年10月，Biogen表示，对数据的重新审视表明，“患者……在认知和功能方面(如记忆、取向和语言)都获得了显著改善。” 两项临床试验中的其中一项试验表明，高剂量的药物确实对减缓阿尔茨海默氏症患者的认知能力下降有微小但显著的效果。Biogen说，它最终将会寻求FDA的批准。</p>
<p><strong>A drug prescribed to even a substantial minority of people with dementia would be among the biggest-sellers of all time.</strong> The price of Biogen’s shares, which had fallen by almost 30% on the day of its announcement that trials had failed, bounced back almost as much when it changed its mind, and surged again a year later when the FDA made positive comments, as well as after its announcement today. Administered intravenously, monthly, at a clinic, aducanumab is likely at first to cost thousands of dollars a year, and patients will require constant monitoring as many develop brain oedemas. </p>
<blockquote>
<p>intravenously 通过静脉</p>
</blockquote>
<p>一种甚至只针对少数痴呆症患者的药物将成为有史以来最畅销的药物之一。在宣布试验失败的当天，Biogen的股价下跌了近30%，但在其改变想法后，股价反弹了几乎同样多。一年后，FDA发表积极评论后，以及在今天宣布后，Biogen的股价再次飙升。aducanumab需要每月在诊所进行静脉注射，一开始可能每年花费数千美元，而且由于许多患者出现脑水肿，患者将需要持续监测。</p>
<p>Many specialists <strong>remain deeply sceptical about</strong> aducanumab in particular, and the amyloid hypothesis more broadly. Last November ten out of the 11 members of an expert advisory panel appointed by the FDA voted against approving the drug on the basis of the research presented (the 11th was undecided). More recently, a new statistical study of various drug trials in Alzheimer’s &amp; Dementia, the journal of the Alzheimer’s Association, a charity, shows what one of its authors, Edo Richard, a Dutch neurologist, calls “<strong>overwhelming evidence</strong> of absence of an effect of anti-amyloid therapy in general”. Dr Richard finds it “amazing” that the FDA has overruled its own advisory panel to reach the “scientifically questionable” ruling on the drug.</p>
<blockquote>
<p>overrule 否决；驳回</p>
</blockquote>
<p>许多专家尤其对aducanumab和更广泛的淀粉样蛋白假说深表怀疑。去年11月，由FDA任命的11位专家咨询小组成员中有10位根据所提交的研究结果投票反对批准该药物(第11位尚未决定)。最近，阿尔茨海默氏症协会(一家慈善机构)的杂志对阿尔茨海默氏症和痴呆症的各种药物试验进行了一项新的统计研究，该研究显示了该研究的作者之一、荷兰神经学家Edo Richard所称的“抗淀粉样蛋白治疗总体上没有效果的压倒性证据”。Richard博士认为“令人惊讶”的是，FDA否决了自己的顾问小组对该药物做出的“科学上有问题”的裁决。</p>
<p>His paper argues that <strong>the time has come to divert</strong> therapeutic efforts <strong>away</strong> from drugs that try to clear beta-amyloid to other lines of investigation. And, for all the scepticism about this drug, some scientists in the field are optimistic that great progress is being made in combating dementia. Jonathan Schott, a professor of neurology at the Dementia Research Centre, University College, London, and chief medical officer of Alzheimer’s Research, says that <strong>30-40% of the causes of dementia are modifiable.</strong> Already there is evidence that the age-specific incidence of dementia is going down in the West as people live healthier lives: obesity, smoking, high blood pressure and excessive drinking in middle age are all associated with a higher incidence of dementia. A study published last year in Neurology followed nearly 50,000 people in America and Europe from 1988 to 2015. It found that 8.6% developed dementia. But the risk of being among them had, remarkably, fallen by an average of about 13% a decade, from about a one-in-four chance for a 75-year-old in 1995 to less than one in five.</p>
<p>他的论文认为，是时候把治疗努力从试图清除β -淀粉样蛋白的药物转移到其他研究方向上了。尽管人们对这种药物持怀疑态度，但该领域的一些科学家乐观地认为，在对抗痴呆症方面正在取得巨大进展。Jonathan Schott是伦敦大学学院痴呆症研究中心的神经学教授，也是阿尔茨海默氏症研究的首席医疗官，他说痴呆的30-40%的原因是可以改变的。已经有证据表明，在西方，随着人们生活得更健康，特定年龄的痴呆症发病率正在下降:中年时期的肥胖、吸烟、高血压和酗酒都与痴呆症的高发病率有关。去年发表在《神经学》杂志上的一项研究从1988年到2015年跟踪调查了美国和欧洲的近5万人。研究发现，8.6%的人患上了痴呆症。但是值得注意的是，成为其中一员的风险十年来平均下降了约13%，从1995年75岁老人的四分之一下降到不到五分之一。</p>
<p>![image-20210614115746499](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&#x2F;image-20210614115746499.png) </p>
<p><strong>Meanwhile, great advances have been made in diagnosing dementia.</strong> Whereas once this required cognitive tests followed by an expensive brain scan or intrusive lumbar puncture, now a simple blood test can predict, decades in advance, how likely it is that someone will develop Alzheimer’s later in life. Identifying those at risk early means that <strong>existing therapies</strong>, including aducanumab, largely ineffective once symptoms are far advanced, <strong>might be deployed early enough to make a difference.</strong> </p>
<p>与此同时，痴呆症的诊断也取得了巨大进展。过去，这需要认知测试，然后进行昂贵的大脑扫描或侵入式腰椎穿刺，而现在，一个简单的血液测试可以提前几十年预测一个人在晚年患上阿尔茨海默氏症的可能性。及早识别风险人群意味着现有的疗法可以及早应用从而发挥作用，因为一旦症状进展到很严重的地步，包括aducanumab在内的现有疗法大多都无效。</p>
<p><strong>And other treatments should, slowly, become available.</strong> James Rowe, a professor of cognitive neurology at Cambridge, believes research into dementia is <strong>at a “tipping-point”</strong>. He expects <strong>the first successes with rare genetic conditions</strong> such as Huntington’s disease and frontotemporal dementia. Alzheimer’s, which may turn out to be an umbrella term for a variety of different contributory pathologies, susceptible to different medicines, would follow later. <strong>Those living with Alzheimer’s have had few reasons for optimism.</strong> And Professor Schott argues that the main benefit of the FDA ruling may be that Alzheimer’s will no longer be seen as a “lost cause”. Big pharma and publicly funded researchers will take encouragement. Aducanumab <strong>offers a small step forward</strong>; bigger ones will come.</p>
<blockquote>
<p>umbrella 综合的</p>
</blockquote>
<p>慢慢地，其他的治疗方法也会出现。剑桥大学认知神经学教授James Rowe认为，对痴呆症的研究正处于一个“临界点”。他希望在罕见的遗传性疾病（如亨廷顿氏病和额颞叶痴呆）方面取得第一批成功。阿尔茨海默氏症将紧随其后，阿尔茨海默氏症可能是一个总称，涵盖了各种不同的致病疾病，对不同的药物敏感。阿尔茨海默氏症患者没有什么乐观的理由。Schott教授认为，FDA裁决的主要好处可能是阿尔茨海默氏症将不再被视为“没有希望的事”。大型制药公司和公共资助的研究人员将受到鼓励。Aducanumab向前迈出了一小步前进;更大的进步将会到来。</p>

      
    </div>
    <footer class="entry-meta entry-footer">
      
      
      
        <div id="donation_div"></div>


<script src="/js/vdonate.js"></script>

<script>
var a = new Donate({
  title: '如果觉得我的文章对您有用，请随意打赏。您的支持将鼓励我继续创作!', // 可选参数，打赏标题
  btnText: 'Donate', // 可选参数，打赏按钮文字
  el: document.getElementById('donation_div'),
  wechatImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/WeChanQR.png',
  alipayImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/AliPayQR.jpg'
});
</script>
      
            
      
        
	<div id="comment">
		<!-- 来必力City版安装代码 -->
		<div id="lv-container" data-id="city" data-uid="MTAyMC8yOTQ4MS82MDQ5">
		<script type="text/javascript">
		   (function(d, s) {
		       var j, e = d.getElementsByTagName(s)[0];

		       if (typeof LivereTower === 'function') { return; }

		       j = d.createElement(s);
		       j.src = 'https://cdn-city.livere.com/js/embed.dist.js';
		       j.async = true;

		       e.parentNode.insertBefore(j, e);
		   })(document, 'script');
		</script>
		<noscript>为正常使用来必力评论功能请激活JavaScript</noscript>
		</div>
		<!-- City版安装代码已完成 -->
	</div>


      
    </footer>
  </div>
  
    
<nav id="article-nav">
  
    <a href="/2021/06/15/Day420-The%20Economist/" id="article-nav-newer" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Newer</strong>
      <div class="article-nav-title">
        
          (no title)
        
      </div>
    </a>
  
  
    <a href="/2021/06/13/Day418-The%20Economist/" id="article-nav-older" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Older</strong>
      <div class="article-nav-title"></div>
    </a>
  
</nav>

  
</article>

<!-- Table of Contents -->

  <aside id="sidebar">
    <div id="toc" class="toc-article" style="overflow-y: scroll; max-width: 28%;">
    <strong class="toc-title">Contents</strong>
    
      <ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#America%E2%80%99s-wary-approval-of-an-Alzheimer%E2%80%99s-drug-offers-hope-to-millions"><span class="nav-number">1.</span> <span class="nav-text">America’s wary approval of an Alzheimer’s drug offers hope to millions</span></a><ol class="nav-child"><li class="nav-item nav-level-6"><a class="nav-link" href="#A-flicker-of-light"><span class="nav-number">1.0.0.0.0.1.</span> <span class="nav-text">A flicker of light</span></a></li></ol></li><li class="nav-item nav-level-5"><a class="nav-link" href="#But-its-makers-still-have-work-to-do-to-prove-it-can-slow-the-advance-of-dementia"><span class="nav-number">1.0.0.0.1.</span> <span class="nav-text">But its makers still have work to do to prove it can slow the advance of dementia</span></a></li></ol></li></ol></li></ol></li></ol></li></ol>
    
    </div>
  </aside>
</section>
        
      </div>
      <footer id="footer" class="site-footer">
  

  <div class="clearfix container">
      <div class="site-info">
	      &copy; 2023 Hexo All Rights Reserved.
          
            <span id="busuanzi_container_site_uv">
              本站访客数<span id="busuanzi_value_site_uv"></span>人次  
              本站总访问量<span id="busuanzi_value_site_pv"></span>次
            </span>
          
      </div>
      <div class="site-credit">
        Theme by <a href="https://github.com/iTimeTraveler/hexo-theme-hiero" target="_blank">hiero</a>
      </div>
  </div>
</footer>


<!-- min height -->

<script>
    var contentdiv = document.getElementById("content");

    contentdiv.style.minHeight = document.body.offsetHeight - document.getElementById("allheader").offsetHeight - document.getElementById("footer").offsetHeight + "px";
</script>

<!-- Custome JS -->

<script src="/js/my.js"></script>

    </div>
    <!-- <nav id="mobile-nav">
  
    <a href="/" class="mobile-nav-link">Home</a>
  
    <a href="/archives" class="mobile-nav-link">Archives</a>
  
    <a href="/categories" class="mobile-nav-link">Categories</a>
  
    <a href="/tags" class="mobile-nav-link">Tags</a>
  
    <a href="/about" class="mobile-nav-link">About</a>
  
</nav> -->
    

<!-- mathjax config similar to math.stackexchange -->

<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    tex2jax: {
      inlineMath: [ ['$','$'], ["\\(","\\)"] ],
      processEscapes: true
    }
  });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Config({
      tex2jax: {
        skipTags: ['script', 'noscript', 'style', 'textarea', 'pre', 'code']
      }
    });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Queue(function() {
        var all = MathJax.Hub.getAllJax(), i;
        for(i=0; i < all.length; i += 1) {
            all[i].SourceElement().parentNode.className += ' has-jax';
        }
    });
</script>

<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.4/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
</script>



  
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.css">

  
<script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.js"></script>




<script src="/js/scripts.js"></script>


<script src="https://stackpath.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>


<script src="/js/main.js"></script>








  <div style="display: none;">
    <script src="https://s95.cnzz.com/z_stat.php?id=1260716016&web_id=1260716016" language="JavaScript"></script>
  </div>



	<script async src="https://dnqof95d40fo6.cloudfront.net/atw7f8.js">
	</script>






  </div>

  <a id="rocket" href="#top" class=""></a>
  <script type="text/javascript" src="/js/totop.js" async=""></script>
</body>
</html>
